

VICANKA~202

### WEEKLY EPIDEMIOLOGICAL REPORT

A publication of the Epidemiology Unit Ministry of Health, Nutrition & Indigenous Medicine

231, de Saram Place, Colombo 01000, Sri Lanka
Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk
Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk
Web: http://www.epid.gov.lk

Vol. 50 No. 05

28th- 03rd Feb 2023

#### **Antimicrobial Resistance Part II**

This is the last article of series of two articles.

# What is the situation today? Resistance in bacteria

Currently, we are running out of effective antibiotics to treat common infections like Urinary tract infections (UTI), Sepsis, sexually transmitted diseases, Tuberculosis, and some form of diarrhoea as high rates of resistance. For example, Ciprofloxacinan antibiotic that is widely used to treat UTIs has high resistant rates varying from 8.4% to 92.9% for Escherichia Coli and from 4.1% to 79.4% for klebsiella pneumonia according to the Global Antimicrobial Resistance and use Surveillance System. (GLASS)

Klebsiella Pneumonia is a bacteria that can cause life-threatening hospital-acquired infections and resistant species to last resource treatment (carbapenem antibiotics) has spread all over the world. Therefore, it has become a challenge to treat hospital-acquired infections such as pneumonia, bloodstream infections, and infections in newborns and intensive-care unit patients.

Colistin is the antibiotic of choice for many carbapenem-resistant bacterial infections. But now colistin-resistant bacteria have been detected in many countries and many regions making it impossible to treat. Staphylococcus aureus is a bacteria found in our skin's normal flora. People with methicillin-resistant Staphylococcus aureus (MRSA) infections are 64% more likely to die than people with drug-sensitive infections. Further, it has become complicated to treat gonorrhoea as wide-spread resistance has been found. Re-

sistance has rapidly emerged to sulphonamides, penicillins, tetracyclines, macrolides, fluoroquinolones, and earlygeneration cephalosporins.

#### **Drug resistance in Mycobacterium Tu**berculosis

WHO estimates that, in 2018, there were about half a million new cases of rifampicin -resistant TB (RR-TB) identified globally, of which the vast majority have multi-drug resistant TB (MDR-TB), a form of tuberculosis that is resistant to the two most powerful anti-TB drugs. Multi-drug-resistant TB needs more expensive and more toxic

	20 15	20 16	20 17	20 18	20 19	20 20	20 21
Number of laboratories that confirmed MDRTB patients	13	17	25	12	21	14	10
Number enrolled in treat- ment in the same year	13	17	24	12	21	14	10
Number enrolled in treat- ment in the next year	1	1	1	ı	1	ı	1
Total number enrolled in treat- ment	13 10 0 %	17 10 0%	24 96 %	12 10 0 %	21 10 0%	14 10 0 %	10 10 0 %



Contents	Page
1. Antimicrobial Resistance Part II	1
2. Summary of selected notifiable diseases reported ( $21^{st} - 27^{th}$ Jan 2023)	3
3. Surveillance of vaccine preventable diseases & AFP (21st - 27th Jan 20	23) 4

drugs for a longer duration to get a cure. Widely spreading MDR TB is a public health issue that needs more concern.

# Table 01 - MDR patients reported and their treatment enrolment 2010 – 2021 in Sri Lanka

In Sri Lanka, there is a very active TB control program under the Ministry of Health. Therefore, the actions like intensive patient detection and timely treatment with proper antibiotics under direct observation have contributed to a low number of MDR TB.

#### Drug resistance in viruses

Antiviral drug resistance in the immunocompromised population is an emerging health issue where resistance has developed to most antiretroviral drugs. (ARV). Therefore, ARV drugs including the newest classes are becoming partially or fully inactive against Human Immunodeficiency Virus (HIV). People receiving antiretroviral therapy can acquire HIVDR, and people can also be infected with HIV that is already drug-resistant. 10% of pretreatment adults are resistant to non-nucleoside reverse transcriptase inhibitors (NNRTI) in the majority of monitored countries in Africa, Asia, and Latin America. In sub-Saharan Africa, over 50% of newly diagnosed HIV infants carry a virus that is resistant to NNRTI. Therefore, the newest WHO-ARV guidelines recommend using Dolutegravir as the first line for adults and children.

#### Drug resistance in Malaria parasites

The emergence of drug-resistant malaria parasites has interfered badly with malaria control and has caused increasing morbidity and mortality. In the WHO Western Pacific Region and the WHO South-East Asia Region, partial resistance to artemisinin and resistance to a number of the ACT partner drugs has been confirmed in Cambodia, Lao People's Democratic Republic, Myanmar, Thailand, and Viet Nam through studies conducted between 2001 and 2019. This makes it very difficult to select the right treatment. And also, the resistant variants of Plasmodium falciparum to sulfadoxinepyrimethamine have led to artesunate-sulfadoxinepyrimethamine failure in some countries, especially in the eastern Mediterranean region. If the resistance to artemisinin and artemisinin-based combination therapypartner drugs spreads further, it could pose a major public health challenge and jeopardize important gains in malaria control.

#### Drug resistance to fungal infections

The prevalence of drug-resistant fungi is higher now. Many fungal infections are still difficult to treat as drug toxicity and existing underlying infections like HIV. Candida auris is one of the most invasive fungal infections which has become resistant to fluconazole, amphoterin B, and voriconazole.

#### Covid 19 pandemic and antibiotic resistance

Although covid 19 is a viral infection, there may be a need for antibiotics when there is a secondary bacterial infection. But there is a high chance of inappropriate use of antibiotics for covid 19 patients and it may drive the spread of resistance against some of our clinically important antibiotics. Few studies done in Wuhan have revealed that almost all covid 19 patients were being treated with antibiotics. So, vaccination against Covid 19 plays an important role in reducing the spread and severity of covid 19 and the chance of using antibiotics. And also, vaccinations against some bacteria that can cause secondary bacterial infections like streptococcus pneumonia and Haemophilus influenza type B can reduce this burden.

#### How to prevent antimicrobial resistance

- Prevent infection and their spread
  - \* Good hygiene
  - \* Vaccinations
  - \* Practice healthy habits around animals
  - Prepare food safely
  - Stay healthy when travelling abroad
  - \* Prevent STDs
- Managing chronic conditions well
- Improve antibiotics and antifungal prescribing by following clinical and treatment guidelines
- Optimal TB treatment with the correct dose, correct combination, and proper duration.
- Be aware of drug-resistant infections and infection patterns in healthcare facilities and take necessary actions to prevent the spread.
- Keep animals healthy in livestock and poultry production

#### Need for coordinated action

AMR is a complex problem that requires a united multisectoral approach. The One Health approach brings together multiple sectors and stakeholders engaged in human, terrestrial, and aquatic animal and plant health, food and feed production, and the environment to communicate and work together in the design and implementation of programs, policies, legislation, and research to attain better public health outcomes.

#### References

- \* https://www.who.int/news-room/fact-sheets/detail/ antimicrobial-resistance
- https://www.gavi.org/vaccineswork/antimicrobialresistance-exacerbating-covid-19-pandemic? gclid=EAIaIQobChMIz9nu39H4\_AIVHtdMAh2-6QATEAAYASAAEgINnPD\_BwE
- \* <a href="https://www.cdc.gov/drugresistance/livestock-poultry-producers.html">https://www.cdc.gov/drugresistance/livestock-poultry-producers.html</a>
- \* https://www.nptccd.health.gov.lk/wp-content/ uploads/2022/12/TB-Annual-Report-2021.pdf

#### Compiled by:

Dr.V.U. Jayasinghe
MBBS
Diploma in Tuberculosis and chest diseases

Table 1: Selected notifiable diseases reported by Medical Officers of Health 21st-27th Jan 2023(4th Week)													)																
0	*5	75	73	7	100	100	71	100	100	93	80	94	65	94	79	100	98	06	93	83	26	75	100	86	93	88	100	06	
WRCD	*_	22	7	4	<b>58</b>	33	46	24	31	24	95	13	31	0	21	34	17	21	22	14	19	22	41	14	27	<b>5</b> 6	4	53	
Leishmania-	В	m	7	0	7	23	0	0	45	6	0	0	0	0	0	0	0	0	44	0	24	46	2	17	17	Н	0	265	
Leishı	A	0	-	0	0	7	0	0	23	7	0	0	0	0	0	0	0	0	12	0	19	18	0	7	3	0	0	82	
gitis	В	0	11	12	1	1	0	П	7	2	0	0	П	П	0	m	7	m	13	6	2	7	m	11	13	9	П	108	
Meningitis	A	0	7	4	0	0	0	0	7	0	0	0	0	0	0	0	0	0	7		က	0	0	7	4	7	0	22	
Chickenpox	В	14	8	21	21	4	8	22	16	11	11	0	0	0	П	8	2	4	33	8	18	4	11	3	7	21	П	255	
Chick	A	0	4	н	m	7	c	2	c	П	0	0	0	0	0	က	0	0	9	7	2	0	Н	7	0	4	0	45	
	В	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Н	
Human	A	0	0	0	0	0	0	0	0	0	П	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	н	
Viral Hep-	В	0	0	П	0	7	0	0	4	П	0	0	0	0	0	0		0	2	0	0	Н	14	0	П		0	28	
Viral	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	7	0	0	0	0	œ	
Sr	В	0	0	0	10	1	9	9	6	2	157	7	1	7	က	0	0	Н	П	m	10	7	7	9	8	Н	0	236	
Typhus	A	0	0	0	П	0	0	က	3		28	0	0	0	0	0	0	0	0	0	7	Н	0	Н	7	0	0	42	
Leptospirosis	В	15	17	40	15	8	8	47	70	32	4	1	2	4	2	12	7	9	31	7	45	19	22	45	69	22	9	204	
Leptos	4	3	7	10	m	П	3	6	6	က	1	0	0	н	Н	н	0	0	7	0	11	4	11	2	14	9	1	10	
Poi-	В	7	0	7	1	0	m	m	0	m	m	0	0	0	0	7	0	0	0	0	П	0	4	0	4	0	0	28	
Food	4	П	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	н	
Dysentery   Encephaliti   Enteric Fever   Food Po	В	0	0	0	0	П	0	0	0	0	П	0	0	0	0	-1	0	0	0	0	0	0	0	0	0	0	0	m	
Ente	⋖	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Н	0	0	0	0	0	0	0	0	0	0	0	н	
phaliti	В	7	7	0	0	0	0	П	0	0	П	0	0	0	0	4	0	0	П	0	0	7	0	0	0	0	0	13	
Ence	4	П	0	0	0	0	0	0	0	0	П	0	0	0	0	Н	0	0	0	0	0	0	0	0	0	0	0	m	
entery	В	0	0	П	2	0	4	က	0	7	4	7	m	m	4	27	-	0	7	0	0	0	4	7	4	0	10	81	
Dys	A	0	0	0	7	0	Н	н	0	Н	0	0	0	0	Н	∞	0	0	0	0	0	0	0	Н	0	0	7	17	
Dengue Fever	В	1083	1021	376	296	123	16	169	79	153	421	14	16	7	4	146	22	125	278	756	26	74	156	36	145	211	512	6295	
Dengu	⋖	279	218	94	72	22	n	48	22	34	70	0	7	1	1	38	1	34	51	117	15	11	38	<b>∞</b>	20	43	108	135	
RDHS		Colombo	Gampaha	Kalutara	Kandy	Matale	NuwaraEliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapur	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmune	SRILANKA	

Table 2: Vaccine-Preventable Diseases & AFP

21st- 27th Jan 2023(4th Week)

Disease	No.	No. of Cases by Province cases during during current s								Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date	
	W	С	S	N	Е	NW	NC	U	Sab	week in 2023	week in 2022	2023	2022	in 2023 & 2022
AFP*	00	00	00	00	00	00	00	00	00	00	02	06	06	0 %
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
Mumps	01	00	01	00	00	01	00	00	00	03	01	09	04	125 %
Measles	00	00	00	00	00	00	00	00	00	00	00	00	01	0 %
Rubella	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
Tetanus	00	00	00	00	00	00	00	00	00	00	00	01	01	0 %
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
Japanese Encephalitis	00	00	00	00	00	00	00	00	00	00	00	00	01	0 %
Whooping Cough	01	00	00	00	00	00	00	00	00	01	00	00	00	0 %
Tuberculosis	156	27	11	07	05	00	02	06	12	226	109	593	385	54.0 %

#### Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam,

AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS,

Special Surveillance: AFP\* (Acute Flaccid Paralysis ), Japanese Encephalitis

CRS\*\* =Congenital Rubella Syndrome

NA = Not Available

### Number of Malaria Cases Up to End of January 2023,

01

## All are Imported!!!

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

#### ON STATE SERVICE

Dr. Samitha Ginige Actg. CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10